A 52-year-old man with a 10-year history of primary open-angle glaucoma presents with progressive superior arcuate visual field defects despite being on topical timolol monotherapy. Intraocular pressure remains elevated at 26 mmHg. Which drug should be added as the next-line agent to reduce intraocular pressure and halt visual field progression?